The Oncologist, Vol. 11, No. 3, 263-273, March 2006; doi:10.1634/theoncologist.11-3-263
© 2006 AlphaMed Press
Large Granular Lymphocyte Leukemia
Lubomir Sokola,
Thomas P. Loughran, Jr.b
a Department of Interdisciplinary Oncology, University of South Florida and H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA;
b Penn State Cancer Institute, Penn State College of Medicine, Hershey, Pennsylvania, USA
Key Words. T-cell LGL leukemia • Aggressive NK-cell leukemia • Cytopenia • Autoimmunity
Correspondence:
Thomas P. Loughran, Jr., M.D., Penn State Cancer Institute, Penn State College of Medicine, 500 University Drive, H072, Hershey, Pennsylvania 17033, USA; Telephone: 717-531-7096; Fax: 717-531-0778; e-mail: tloughran{at}psu.edu
Clonal disorders of large granular lymphocytes (LGLs) represent a spectrum of biologically distinct lymphoproliferative diseases originating either from mature T cells (CD3+) or natural killer (NK) cells (CD3). Both subtypes, T-cell and NK-cell LGL leukemia, can manifest as indolent or aggressive disorders. The majority of patients with T-cell LGL leukemia have a clinically indolent course with a median survival time >10 years. Immunosuppressive therapy with low-dose methotrexate, cyclophosphamide, or cyclosporine A can control symptoms and cytopenias in more than 50% of patients, but this approach is not curative. Several cases of an aggressive variant (CD3+CD56+) of T-cell LGL leukemia with a poor prognosis have also been reported. Aggressive NK-cell LGL leukemia is usually a rapidly progressive disorder associated with Epstein-Barr virus (EBV), with a higher prevalence in Asia and South America. This disease is usually refractory to conventional chemotherapy, with a median survival time of 2 months. Chronic NK-cell leukemia/lymphocytosis is a rare EBV-negative disorder with an indolent clinical course. The malignant origin of this subtype is uncertain because clonality is difficult to determine in LGLs of NK-cell origin.
This article has been cited by other articles:

|
 |

|
 |
 
Y.-Y. Hwang, A. Y.H. Leung, I. O.L. Ng, G. S.W. Chan, K.-W. Chan, E. Tse, and Y.-L. Kwong
Protein-Losing Enteropathy Due to T-Cell Large Granular Lymphocyte Leukemia
J. Clin. Oncol.,
April 20, 2009;
27(12):
2097 - 2098.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Chen, F. Bai, L. Sokol, J. Zhou, A. Ren, J. S. Painter, J. Liu, D. A. Sallman, Y. A. Chen, J. A. Yoder, et al.
A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia
Blood,
April 2, 2009;
113(14):
3226 - 3234.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Rodriguez-Caballero, A. C. Garcia-Montero, P. Barcena, J. Almeida, F. Ruiz-Cabello, M. D. Tabernero, P. Garrido, S. Munoz-Criado, Y. Sandberg, A. W. Langerak, et al.
Expanded cells in monoclonal TCR-{alpha}{beta}+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis recognize hCMV antigens
Blood,
December 1, 2008;
112(12):
4609 - 4616.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Zhang, M. V. Shah, J. Yang, S. B. Nyland, X. Liu, J. K. Yun, R. Albert, and T. P. Loughran Jr.
Network model of survival signaling in large granular lymphocyte leukemia
PNAS,
October 21, 2008;
105(42):
16308 - 16313.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. V. Shah, R. Zhang, R. Irby, R. Kothapalli, X. Liu, T. Arrington, B. Frank, N. H. Lee, and T. P. Loughran Jr
Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes
Blood,
August 1, 2008;
112(3):
770 - 781.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. W. Wlodarski, Z. Nearman, A. Jankowska, N. Babel, J. Powers, P. Leahy, H.-D. Volk, and J. P. Maciejewski
Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL leukemia
J. Leukoc. Biol.,
March 1, 2008;
83(3):
589 - 601.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Thomas, J. K. Haseman, J. I. Goodman, J. M. Ward, T. P. Loughran Jr, and P. J. Spencer
A Review of Large Granular Lymphocytic Leukemia in Fischer 344 Rats as an Initial Step Toward Evaluating the Implication of the Endpoint to Human Cancer Risk Assessment
Toxicol. Sci.,
September 1, 2007;
99(1):
3 - 19.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2006 by AlphaMed Press.
|
|